

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

CHO-K1

RRID:CVCL_0214

Type: Cell Line

Proper Citation

Ubigen Cat# YC-C066, RRID:CVCL_0214

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0214

Proper Citation: Ubigen Cat# YC-C066, RRID:CVCL_0214

Description: Cell line CHO-K1 is a Spontaneously immortalized cell line with a species of origin *Cricetulus griseus* (Chinese hamster)

Sex: Female

Defining Citation: [PMID:10320750](#), [PMID:21804562](#), [PMID:21945585](#), [PMID:22971049](#), [PMID:23873082](#), [PMID:26993211](#), [PMID:28544881](#), [PMID:32078082](#), [PMID:32619503](#), [PMID:34050613](#), [PMID:34737324](#), [PMID:36610518](#)

Category: Spontaneously immortalized cell line

Organism: *Cricetulus griseus* (Chinese hamster)

Name: CHO-K1

Synonyms: CHO K1, CHOK1, CHO cell clone K1, GM15452

Cross References: BTO:BTO_0000457, CLO:CLO_0002427, CLO:CLO_0002462, CLO:CLO_0002463, CLO:CLO_0026669, CLO:CLO_0050409, CLO:CLO_0050420, CLO:CLO_0050423, EFO:EFO_0022782, MCCL:MCC:0000103, CLDB:cl730, CLDB:cl731, CLDB:cl732, CLDB:cl734, CLDB:cl735, CLDB:cl738, CLDB:cl739, CLDB:cl740, CLDB:cl741, CLDB:cl4897, AddexBio:P0017001/33, ATCC:CCL-61, ATCC:CRL-9618, BCRC:60006, BCRJ:0069, CCLV:CCLV-RIE 0134, CCLV:CCLV-RIE 0315, CCRID:1101HAM-PUMC000004, CCRID:1102HAM-NIFDC00006, CCRID:3101HAMGNHa7, CCRID:3101HAMSCSP507, CCRID:4201HAM-CCTCC00018, CCRID:4201PAT-CCTCC00006, CCRID:5301HAM-KCB88028YJ, CCRID:6101MOU-CERC000111, CCTCC:GDC0018, ChEMBL-Cells:ChEMBL3307512, ChEMBL-Targets:ChEMBL614031, CLS:603480, Coriell:GM15452, DSMZ:ACC-110, DSMZCellDive:ACC-110, ECACC:85051005, GEO:GSE92885, GEO:GSM1968555,

GEO:GSM1968556, GEO:GSM1968557, GEO:GSM1968558, GEO:GSM1968559, GEO:GSM1968560, GEO:GSM1968561, GEO:GSM1968562, GEO:GSM1968563, GEO:GSM1968564, GEO:GSM1968565, GEO:GSM1968566, GEO:GSM1968567, GEO:GSM1968568, GEO:GSM1968569, GEO:GSM1968570, GEO:GSM1968571, GEO:GSM1968572, GEO:GSM1968589, GEO:GSM1968591, GEO:GSM1968593, GEO:GSM1968594, GEO:GSM1968595, GEO:GSM1968596, GEO:GSM1968597, GEO:GSM1968598, GEO:GSM1968599, GEO:GSM1968600, IBRC:C10136, ICLC:ATL98003, IZSLER:BS CL 15, JCRB:IFO50414, JCRB:JCRB9018, KCB:KCB 88028YJ, KCLB:10061, Lonza:44, MetaboLights:MTBLS493, NCBI_Iran:C645, PubChem_Cell_line:CVCL_0214, RCB:RCB0285, RCB:RCB2330, RCB:RCB2869, TKG:TKG 0328, TOKU-E:949, TOKU-E:950, Ubigene:YC-C066, Wikidata:Q54812705

ID: CVCL_0214

Vendor: Ubigene

Catalog Number: YC-C066

Hierarchy: cvcl_0213

Record Creation Time: 20250130T070723+0000

Record Last Update: 20260905T184001+0000

Ratings and Alerts

No rating or validation information has been found for CHO-K1.

No alerts have been found for CHO-K1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 3039 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Du R, et al. (2026) miRNA modules for precise, tunable control of gene expression. Molecular cell, 86(1), 194.

Wan YH, et al. (2026) Monoclonal neutralizing antibodies elicited by infection with Kaposi sarcoma-associated herpesvirus reveal critical sites of vulnerability on gH/gL. PLoS pathogens, 22(1), e1013772.

Kim YW, et al. (2026) Therapeutic potential of small molecules that block receptor-induced Kv7/M-current suppression in neuroprotection, seizures, and pain. British journal of pharmacology, 183(13), 3780.

- Cole EB, et al. (2026) IL-7/IL-15/IL-21 cytokine-fusion scaffold generates highly functional CAR T cells enriched in long-lived T memory stem cells. *Science advances*, 12(11), eaec2632.
- Pan Y, et al. (2026) Engineering novel AAV capsids by broadly attenuated and subsequent muscle-specific tropism in mice and NHPs. *Molecular therapy. Advances*, 34(2), 201725.
- Peng Y, et al. (2026) SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors. *Molecular cancer therapeutics*, 25(2), 322.
- Saini P, et al. (2026) Targeting Interactions Between Siglec-10 and $\alpha 5 \beta 1$ Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. *Cancer research*, 86(1), 99.
- Aliyu L, et al. (2026) Glycoform engineering of a mammalian platform to sculpt a humanized recombinant bioscavenger. *Cell systems*, 101655.
- Janoušková-Randáková A, et al. (2026) Dualsteric and dual-acting modulation of muscarinic receptors by antagonist KH-5. *British journal of pharmacology*.
- Barrio-Calvo M, et al. (2026) An Exploratory Study of the Impact of a CCL21-Derived C-Terminal Peptide on Dendritic Cell Lymph Node Homing. *Journal of immunology research*, 2026, 8833079.
- Frapolli R, et al. (2026) Dinutuximab beta effectively treats Ewing sarcoma when combined with chemotherapy. *iScience*, 29(1), 114449.
- Audebrand A, et al. (2026) Second-generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy-induced toxicity. *British journal of pharmacology*, 183(12), 3377.
- Jaber A, et al. (2026) Contact sensitizers activate keratinocytes and induce cytotoxicity via Transient Receptor Potential Ankyrin 1 in allergic contact dermatitis. *British journal of pharmacology*, 183(16), 4610.
- Cordeiro S, et al. (2026) Natural xanthenes as α -Mangostin induce vasorelaxation involving key gating residues in the S6 domain of BK channels. *eLife*, 14.
- Chavez B, et al. (2026) Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides. *Cancer biology & therapy*, 27(1), 2688479.
- Passeri D, et al. (2026) Structure-Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off-Target Effects. *ChemMedChem*, 21(2), e202500960.
- Ogami R, et al. (2026) Histamine H1 Receptor-Mediated CREB Phosphorylation via Gq Protein Signaling and Arrestin Modulation. *Pharmaceuticals (Basel, Switzerland)*, 19(2).
- Cai J, et al. (2026) LM-101, an Anti-SIRP α Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I

Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(12), 2391.

Li S, et al. (2026) Rationally designed light-inducible RNA-releasing protein for translational regulation and optogenetic control of gene therapies. Trends in biotechnology.

Aouad S, et al. (2026) Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy. Journal for immunotherapy of cancer, 14(4).